This blog covers:
- Why follow-ups in pharmacovigilance are essential incase management.
- How to prioritise cases for follow-up based on seriousness and clinical significance.
- How to design effective follow-up strategies to obtain complete and clinically relevant information.
Introduction
Receiving an adverse drug reaction (ADR) report is only the beginning of the pharmacovigilance process. In many cases, the information provided in the initial report is incomplete, and important details about the patient, suspected medicinal product, reaction, treatment, or clinical outcome may be missing.
This is where follow-up becomes essential.
Follow-up is not simply about contacting a reporter to ask a few additional questions. It is a structured process designed to obtain clinically relevant information, improve the quality of individual case safety reports (ICSRs), and support the ongoing assessment of a medicinal product’s safety profile.
But why are some cases prioritised for follow-up over others? What information should companies request, and how should they approach reporters? Let’s explore the purpose of follow-up and the practical considerations involved in managing it effectively.
“Effective follow-ups in pharmacovigilance are more than just collecting missing information; they are about completing the safety story, strengthening case assessment, and supporting better decisions for patient safety.”
Why Is Follow-Up Necessary in Pharmacovigilance?
The primary purpose of follow-up is to obtain additional information that helps clarify a reported adverse reaction and improve the completeness of the safety case.
Several factors make follow-up an important part of routine pharmacovigilance activities.
1. Initial Reports Are Often Incomplete
When an ADR report is first received, the available information may be limited. For example, the reporter may describe the reaction but omit the date of onset, dosage, treatment duration, relevant medical history, concomitant medications, or the patient’s outcome.
In other cases, the report may contain only a brief description of the event, making it difficult to understand the clinical circumstances.
Follow-up provides an opportunity to clarify these gaps and obtain additional details that may be important for case processing and medical assessment.
2. To Improve Case Completeness and Safety Assessment
Missing information can affect the interpretation of a case. Details about the timing of the reaction, changes in treatment, relevant investigations, dechallenge or rechallenge, and the patient’s recovery may help medical reviewers evaluate the available evidence.
Obtaining additional information does not necessarily establish that a medicinal product caused the reaction. However, it can provide a stronger basis for assessing the case and identifying information that may require further investigation.
3. To Collect Information Relevant to the Specific Case
Follow-up should be planned according to the information missing from each report. A standard set of questions may be useful, but the most effective approach is to identify what is already known and what additional information would meaningfully clarify the case.
For example, if the report concerns a suspected hepatic reaction, relevant follow-up information may include liver function test results, the timing of laboratory abnormalities, concomitant medications, and the clinical course.
The questions should be targeted to the reported event rather than asking the reporter to provide every possible detail.
4. To Establish the Outcome of Serious Cases
For serious adverse drug reactions, follow-up may need to continue after the initial report has been submitted.
Where appropriate and feasible, additional information should be sought until the patient’s outcome is established or the clinical condition has stabilised. This may include information about recovery, persistent symptoms, disability, hospitalisation, or death, depending on the case.
New information received after the initial submission should be assessed and processed in accordance with the applicable reporting requirements and timelines.
5. To Improve Selected Reports When Complete Information Is Unavailable
Ideally, comprehensive information would be available for every safety case. In practice, however, reporters may not respond, records may be inaccessible, or the available information may remain limited despite repeated attempts.
Companies should therefore make reasonable, documented efforts to obtain additional information, prioritising cases where the expected benefit of follow-up is greatest. Reports received indirectly or through second-hand sources may also warrant follow-up when additional details could be obtained.
The objective is to make appropriate efforts to improve the available evidence without assuming that every missing detail can necessarily be recovered.
How Should Companies Prioritise Follow-Up?
Not every case requires the same level of follow-up effort. When resources are limited, prioritisation helps companies focus on reports where additional information may have the greatest safety or regulatory value.
A prioritisation approach described in pharmacovigilance guidance places the following categories in order:
- Serious and unexpected cases
- Serious and expected cases
- Non-serious and unexpected cases
Cases of special interest should also receive additional attention. Examples include adverse reactions subject to active surveillance requested by regulatory authorities and cases that could contribute to a decision about changing product labelling.
This priority order should be applied in the context of the relevant regulatory requirements, company procedures, and the clinical significance of the case.
Prioritisation does not mean that other reports should automatically be excluded from follow-up. Rather, it helps determine where follow-up resources should be directed first.
Practical Considerations When Conducting Follow-Up
Obtain Written Confirmation Where Possible
When important details are provided during a telephone conversation, written confirmation should be obtained whenever feasible. This helps ensure that the information is captured accurately and can be reviewed during subsequent case processing.
The communication and information received should be documented in the safety database according to the applicable procedures.
In exceptional circumstances, if a reporter refuses to provide additional information, a marketing authorisation holder may be able to seek assistance from a regulatory authority, where the relevant legal framework permits it.
To Use Appropriate Follow-Up Methods
Depending on the circumstances, follow-up information may be requested through a telephone call, written correspondence, a site visit, or another appropriate communication method.
Requests should clearly identify the missing information and contain specific questions for the reporter. Targeted questionnaires or dedicated forms can also help collect clinically relevant information in a consistent manner.
Where possible, written confirmation of information initially provided verbally should be obtained to support accurate case documentation.
To Involve Appropriately Trained Personnel
Follow-up can require more than administrative communication. Some cases involve complex clinical circumstances and need questions that reflect an understanding of the reported reaction and the relevant therapeutic area.
Ideally, healthcare professionals with appropriate pharmacovigilance training and therapeutic expertise should be involved in collecting follow-up information, particularly for medically significant cases.
Their involvement can help ensure that questions are relevant, clear, and appropriate to the clinical situation.
Retain Sufficient Contact Information
At the time of the initial report, companies should make reasonable efforts to obtain and retain sufficient information about the patient and reporter to support potential follow-up.
This may include appropriate contact details and other information needed to identify the case and request clarification. Such information must be handled in accordance with applicable data protection and privacy requirements.
Collecting appropriate contact information at intake can prevent avoidable difficulties when additional information is needed later.
Determine How Long Follow-Up Should Continue
There is no single follow-up duration that is suitable for every case. The appropriate approach depends on the seriousness of the reaction, the clinical circumstances, the information still required, the reporter’s availability, and applicable regulatory requirements.
For serious cases, efforts to obtain clinically important information may need to continue until the outcome is established or the condition stabilises, where feasible.
Companies should document their attempts, responses, and decisions about further follow-up in accordance with their procedures.
Follow-Up of Pregnancy Exposure Reports
Pregnancy exposure reports require particular attention because the potential effects of medicinal product exposure on the embryo or foetus may not be immediately apparent.
Pharmacovigilance guidance expects marketing authorisation holders to follow up pregnancy reports received from healthcare professionals or consumers when an embryo or foetus could have been exposed to one of their medicinal products.
The assessment of potential exposure should not be limited to whether the medicinal product was taken during a recognised gestational period. When an active substance or its metabolites have a long half-life, exposure from treatment taken before pregnancy or before the relevant gestational period may also need to be considered.
Follow-up may therefore be important for clarifying the timing of exposure, the course of the pregnancy, relevant maternal and foetal information, and the eventual outcome, as appropriate to the circumstances and applicable guidance.
The information requested should be clinically relevant, proportionate, and collected with due regard for privacy and applicable requirements.
Conclusion
Follow-up is an essential part of effective pharmacovigilance case management. It helps companies clarify incomplete reports, obtain clinically meaningful information, assess serious cases more effectively, and improve the evidence available for ongoing safety monitoring.
Effective follow-up is not measured simply by the number of times a reporter is contacted. Its value lies in asking the right questions, prioritising cases appropriately, documenting communication attempts, and using the information obtained to improve the quality of safety assessments.
By applying a structured and risk-based approach, pharmacovigilance teams can make better use of their resources while supporting the continuous monitoring of medicinal product safety.
